Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
Status:
Active, not recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
This research study is studying the combination of a drug called atezolizumab and a radiation
procedure called stereotactic radiosurgery (SRS) as a possible treatment for triple-negative
breast cancer that has spread to the brain.
The interventions involved in this study are:
- Atezolizumab
- Stereotactic radiosurgery (SRS)